Salient Conclusive Remarks on Epidemiology and Clinical Manifestations of Pediatric COVID-19: Narrative Review

Abdelwahid Saeed Ali1, Ahmed Mossa Al-Hakami1, Ayed Abdullah Shati2

  • 1Department of Microbiology and Clinical Parasitology, College of Medicine, King Khalid University, Abha, Saudi Arabia.

Frontiers in Pediatrics
|December 18, 2020
PubMed

Insights

Pediatric COVID-19, caused by SARS-CoV-2, is generally mild, with lower infection and mortality rates compared to adults. Transmission primarily occurs from adults, and severe cases are often linked to existing comorbidities.

Area of Science:

  • Virology and Epidemiology
  • Pediatric Infectious Diseases

Background:

  • The COVID-19 pandemic, caused by SARS-CoV-2, has presented global public health challenges.
  • While COVID-19 affects all age groups, understanding pediatric epidemiology and pathology remains crucial.
  • Existing literature on pediatric COVID-19 lacks conclusive epidemiological and pathological data.

Purpose of the Study:

  • To review and elucidate the epidemiological characteristics of pediatric COVID-19.
  • To describe the clinical phenotypes and outcomes of COVID-19 in children.
  • To analyze factors contributing to lower infection and severity rates in pediatric populations.

Main Methods:

  • A narrative review of scientific literature on pediatric COVID-19.
  • Data compilation and analysis from December 2019 to October 2020.
  • Focus on age-related infection, virus acquisition, and clinical manifestations.

Main Results:

  • Children of all ages, including neonates, can contract SARS-CoV-2.
  • Pediatric COVID-19 is typically less common and presents with milder symptoms compared to adults.
  • Adults are the primary source of infection for children; intrauterine and breastfeeding transmission are not confirmed.
  • Infection, morbidity, and mortality rates in children are significantly lower than in adults and previous coronavirus epidemics (SARS-CoV, MERS-CoV).
  • Clinical presentations in children often resemble adult phenotypes, with complications linked to comorbidities.

Conclusions:

  • COVID-19 in children generally follows a benign clinical course with lower infectivity and mortality.
  • Comorbidities play a significant role in the severity and complications of pediatric COVID-19.
  • Further research is needed to fully understand the long-term implications and specific vulnerabilities in children.

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.6K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
109
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
135
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
90
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
110
Introduction to Epidemiology01:26

Introduction to Epidemiology

Epidemiology, known as the cornerstone of public health, involves studying the distribution and determinants of health-related events in defined populations and applying these insights to control health issues. This is essential for understanding how diseases spread, identifying populations at greater risk, and implementing measures to control or prevent outbreaks. Epidemiology addresses not only infectious diseases but also non-communicable conditions like cancer and cardiovascular disease,...
1.4K